PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29132714.
- Also identified by DOI 10.1016/j.eururo.2017.10.027 and PMC identifier 6859641.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The use of [<sup>18</sup>F]- and [<sup>68</sup>Ga]-labeled inhibitors of prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of prostate cancer is now widespread. We have proposed a reporting and data system called PSMA-RADS version 1.0, which is a framework for classifying PSMA-targeted PET scans and individual findings into categories that reflect the likelihood of the presence of prostate cancer.
Medical subject headings
- Positron-Emission Tomography
- Prostate
- Prostate-Specific Antigen
- Prostatic Neoplasms
- Research Design